SPRC logo

SCISPARC LTD

SPRCNASDAQ
🏆 #5312 by market capUS Equity
$0.81—
Last available close · quote unavailable
🔔
Track SPRC
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d▼ 32.9%
14d▼ 60.1%
30d▼ 84.5%
ytd▼ 93.4%
1y▼ 97.4%
🏦Market Cap
$487,257
Small Cap
📈Revenue Growth (YoY)
-34.5%
Declining
📊Gross Margin
64.5%
High
💵FCF Margin
-859.6%
Thin
⚖️P/S Ratio
0.7x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
—
52-Week Range
$0.73 – $34.65
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
573,243
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$856,000
Last Q Revenue
$284,000
P/E Ratio
-0.0
P/S Ratio
0.7x
EPS (TTM)
$-14.85
Dividend Yield
0.00%
Dilution (1yr)
−82.0%
SPRC logo

SCISPARC LTD

SPRC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$856K▼ −34.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
73.7%▲ +90.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$9M▲ +19.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$4M▼ −18.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
41K▼ −82.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$4M▲ +$3M YoY
StockOtter · stockotter.space

About SCISPARC LTD

SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.